In a placebo-controlled trial, clinical benefits were apparent at 6 months, but other endpoints were inconsistent.
Minocycline showed early promise as a disease-modifying therapy for multiple sclerosis (MS) with favorable pricing. In this multicenter study, conducted from 2009 through 2013, investigators recruited 142 participants with clinically isolated syndrome (by 2005 McDonald criteria) or early MS (by 2010 criteria), and randomized them 1:1 to 100 mg minocycline twice daily or placebo.
A significant reduction in confirmed diagnosis by 2005 McDonald criteria was observed at 6 months (the primary endpoint); after adjustment for baseline magnetic resonance imaging (MRI) enhancing lesion number, rates of conversion were 43% with minocycline versus 62% with placebo. However, conversion and MRI outcomes were not significant at 24 months. Side effects inc…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)